Eculizumab may be useful for dense deposit disease and C3 glomerulonephritis

A new proof-of-concept study reports that eculizumab treatment may be effective in some cases of dense deposit disease and C3 glomerulonephritis. Bomback et al. treated three patients with dense deposit disease and three patients with C3 glomerulonephritis every other week for 12 months. After this time, serum creatinine levels had decreased in two patients, one patient showed decreased proteinuria, and one patient showed stable laboratory parameters but histologic improvements.